2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Iron Overload, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

2884 Iron deficiency anemia in young females is associated with increased mental health and neurocognitive dysfunction

Yonca Cam, PhD, Zhang Jingyi, MS2, Heather Roberts, MS3, Stephen J. Thomas, PhD4, Amy Mirro, MEng5, Sameera Faiz, MD6, Vedika Mullay7, Kristin Guilliams, MD, MSCI8, Melanie Fields, MD, MSCI9
1 Washington University in St, Louis, Saint Louis, Missouri, United States
2 Washington University in St. Louis, Saint Louis, Missouri, United States
3 Washington University in St. Louis, Saint Louis, Missouri, United States
4 University of Alabama at Birmingham, Birmingham, Alabama, United States
5 Washington University in St, Louis, Saint Louis, Missouri, United States
6 Washington University in St, Louis, Saint Louis, Missouri, United States
7 Washington University in St, Louis, Saint Louis, Missouri, United States
8 Washington University in St, Louis, Saint Louis, Missouri, United States, Washington University in St. Louis, Saint Louis, Missouri, United States, Washington University in St. Louis, Saint Louis, Missouri, United States
9 Washington University in St, Louis, Saint Louis, Missouri, United States, Washington University in St. Louis, Saint Louis, Missouri, United States

Iron deficiency anemia (IDA) is the most prevalent nutritional deficiency worldwide, and approximately 1 in 16 adolescent females have IDA, with rates significantly higher among minority groups in the U.S. Iron is essential for healthy brain development through its roles in myelination, regulation of serotonin, dopamine, and norepinephrine and glutamate and γ-aminobutyric acid homeostasis, which are critical for both emotional regulation and cognitive function. However, the effects of IDA on behavioral and neurocognitive outcomes remain poorly understood.

Participants with IDA and healthy controls (HC) between the 9 and 18 years of age were enrolled in this single-site study. Participants completed assessments of sleep (PROMIS Sleep Disturbance and Sleep-Related Impairment), fatigue (PedsQL Multidimensional Fatigue Scale), anxiety (Multidimensional Anxiety Scale for Children 2), depression (Children's Depression Inventory 2), and cognition (NIH Toolbox Cognition Battery). Hemoglobin (Hb) and ferritin were obtained at the time of data collection. Data are presented as median [interquartile range] and compared with the Wilcoxon rank-sum or Fisher’s Exact test. Bivariate correlations were performed with Spearman’s ρ test. Multivariate linear regressions were performed to examine the relationship between Hb and each main outcome, anxiety, depression, and cognition, while controlling for sleep disturbance.

Fifty-two participants (29 IDA, 23 HC) completed study visits. Cohorts were comparable in age (HC (15 [11.7, 18.0] years, IDA (17 [16.0, 17.0] years, p=.06). Hb and ferritin were lower in the IDA cohort (9.4 [8.0, 10.3] g/dL; 8.0 [6.0, 14.3] ng/mL) compared to HC (12.8 [12.4, 13.4] g/dL, p<.001; 25.0 [15.5, 42.0] ng/mL, p<.001). Compared to HC, participants with IDA had significantly worse sleep disturbance (p=.023), sleep-related impairment (p=.004), general fatigue (p=.005), total anxiety (p=.005), and total depressive symptom severity (p=.006), as well as lower fluid cognition (p=.01) and executive functioning scores (p=02). Participants with IDA had higher scores than HC across all subdomains of anxiety (separation anxiety (p=.04), generalized anxiety (p=.01), social anxiety (p=.03), performance fears (p=.02), obsessive-compulsive symptoms (p=.007), physical symptoms (p=.02), panic (p=.02), harm avoidance (p=.03)). Regression models showed that lower Hb levels were associated with greater overall anxiety (β=−2.02, Cl[-3.53, -0.52], p=.03), separation anxiety (β=−2.08, Cl[-3.63, -0.53], P=.03), and obsessions and compulsions (β=−2.02, Cl[-3.74, -0.95], p=.029) while controlling for sleep disturbance.

Participants with IDA had increased depressive symptoms in the domains of emotional problems (p=.003), negative mood/physical symptoms (p=.002), functional problems (p=.03), and ineffectiveness (p=.03). Both lower Hb and ferritin levels were correlated with higher total depression (Hb ρ=−0.428, p=.002; ferritin ρ=−0.431, p=.001), emotional problems (Hb ρ=−0.444, p=.001; ferritin ρ=−0.393, P=.004), negative mood/physical symptoms (Hb ρ=−0.446, p=.001; ferritin ρ=−0.359, p=.009), functional problems (Hb ρ=−0.338, p=.014; ferritin ρ=−0.390, p=.004), ineffectiveness (Hb ρ=−0.315, p=.023; ferritin ρ=−0.374, p=.006), and interpersonal problems (Hb ρ=−0.295, p=.034; ferritin ρ=−0.292, p=.04). However, in regression models, Hb was not associated with depression outcomes after adjusting for sleep disturbance. Hb was correlated with fluid intelligence (ρ=0.318, p=.02) and executive functioning (ρ=0.316, p=.03), while ferritin was only correlated with executive functioning (ρ=0.282, p=.05). Yet, Hb was not associated with cognitive outcomes after adjusting for sleep disturbance.

            Our IDA cohort had greater sleep disturbance, sleep-related impairment, fatigue, anxiety, and depressive symptoms compared to HC, and greater symptom severity was associated with lower Hb and ferritin. Hb was associated with various anxiety domains after controlling for sleep disturbance, which was not observed for depression-related outcomes, suggesting the effects of IDA may be more pronounced for anxiety-related behavior. In our cohort, we did not find an association between Hb and cognitive outcomes after adjusting for sleep. However, further investigations are required to confirm these findings in a larger cohort and to determine whether the effects of IDA on mental health improve following iron repletion.

Yonca Cam, PhD: No relevant conflicts of interest to declare.